In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Veracyte Inc. (NASDAQ:VCYT) reported that Acuta Capital Partners, Llc has picked up 3,888,161 of common stock as of 2017-08-03.
The acquisition brings the aggregate amount owned by Acuta Capital Partners, Llc to a total of 3,888,161 representing a 11.5% in the company.
For those not familiar with the company, Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.
A glance at Veracyte Inc. (NASDAQ:VCYT)’s key stats reveals a current market capitalization of 279.96M based on 33.89M shares outstanding and a price at last close of $8.26 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2016-06-03, Anderson picked up 2,500 at a purchase price of $5.32 per share.This brings their total holding to 10,000 as of the date of the filing.
On the sell side, the most recent transaction saw Treu unload 2,226 shares at a sale price of $8.08. This brings their total holding to 20,504.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Veracyte Inc. (NASDAQ:VCYT) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.